Replies to post #148783 on NorthWest Biotherapeutics Inc (NWBO)

[Truthfan]

You can believe this or not, but the evidence is striking in my opinion to anyone who has a reasonable grasp of the inner dealings of Wall Street, Big Pharma, and Government Regulators and Politicians. What I see and hear on this board does not make me believe many retail investors understand these issues and the complexities involved.

Exactly!

Stay strong - The force is with you

[inveterate]

Thank you for presenting a scenario that, to me, seems most likely. Perhaps I am naive, but I do not believe that the management team has been motivated by personal gain through all these years. Of course, we are all anxious and want to see some resolution sooner rather than later but, at some point, we have to put our trust in our pilots.

[Tadasana]

Thanks iwasadiver, authentic post, much appreciated.

[AVII77]

I think there's a real possibility that NWBO is on the verge of approval and that because of this the company has gone into silent mode. Period. Nothing else makes any sense at all.

Nothing else makes any sense?

How about this:

"Beyond these primary questions of materiality and scienter, it is important to note that a company cannot be liable for failing to publicize a fact, even if the fact is material, unless the company has an obligation to disclose it. In the context of disclosures of negative clinical trial results, a duty to disclose a non-public material fact may arise if the company makes statements that will mislead unless the company also reveals the negative test results. This duty arises from sections 11 and 12(a)(2) of the 1933 Act and Rule 10b-5, which expressly impose liability for omitting material facts necessary to make statements made non-misleading. Likewise, section 10(b) cases hold that “when a corporation does make a disclosure—whether it be voluntary or required—there is a duty to make it complete and accurate.” Applied in the context of pharmaceutical companies, where a drug or device company “has reached a conclusion that test results on a new product are negative, it may, as a practical matter, be difficult to provide any progress report on the product to the investment community that fails to include this ‘bad’ news without the report being arguably incomplete or misleading.”"

That makes a lot of sense to me. And it is a lot different than "on the verge of approval".

[john1045]

So very well said! Thanks for sharing and in agreement with you 100%!